Apple has called upon the Federal Circuit, urging them to allow the tech company to continue selling Apple Watches. The appeal comes after the U.S. International Trade Commission (ITC) claimed that the blood oxygen monitor incorporated in the watch infringes on Masimo’s patents.
In its appeal, Apple labeled the arguments made by the ITC and Masimo for an import ban as “procedurally improper” and “fundamentally unfair”. These arguments have sprung into existence due to the ongoing patent infringement case related to the blood oxygen monitoring feature in the Apple Watch’s original design.
The technology giant maintains, despite swirling controversy and opposing claims by both the ITC and Masimo, that it should be allowed to keep its original Apple Watch for sale on the global market.
The unfolding legal battle sheds light on the tensions at play between patent protection and product innovation in the technology landscapes. Further details about this evolving situation as well as additional updates on the case are available on
Law360.